Genmab will receive 10% in royalties from sales of Kesimpta.
发布者：BY MARKETWIRE，转转请注明出处：https://robotalks.cn/novartis-reports-continued-sales-growth-of-genmab-developed-sclerosis-drug/
Novartis reports continued sales growth of Genmab-developed sclerosis drug
赞 (0)
关于作者
Centerra continues gold junior investment spree with acquisition of Azimut stake
上一篇
29 4 月, 2025 5:17 下午
AstraZeneca CEO warns against US tariffs on medicines
下一篇
29 4 月, 2025 5:19 下午
相关推荐
-
All you need to know about MUDA scam in which Karnataka CM faces prosecution
Earlier, a problem was submitted by social lobbyist Snehamayi Krishna versus centimeters Siddaramaiah and 9 others for presumably creating papers to assert settlement from the Mysu…
-
AI transforms network security amid remote work challenges
The globe of network safety and security is being considerably influenced by expert system, the surge of the information lake and the implications of a pandemic that compelled busi…
-
Fact of the Day – 12/18/2024
Gartner projections around the world semiconductor income will certainly expand 14% in 2025. The blog post Fact of the Day – 12/18/2024 initially showed up on Connected World.
-
Palo Alto Networks buys Protect AI for reported $500M+, debuts new cybersecurity tools
Palo Alto Networks Inc. is expanding its product portfolio with a new platform for protecting artificial intelligence models and an upgraded version of its security-optimized brows…
-
PAR Technology Corporation Announces Proposed Offering of $100 Million of Convertible Senior Notes
NEW HARTFORD, N.Y.–( SERVICE CABLE)– The Same Level Innovation Company (NYSE: THE SAME LEVEL) (” Business” or “THE SAME LEVEL”) revealed today i…
